<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Turcu AF</submitter><funding>NIDDK NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>604-613</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10922262</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>81(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Primary aldosteronism (PA) has been broadly dichotomized into unilateral and bilateral forms. Adrenal vein sampling (AVS) lateralization indices (LI) ≥2 to 4 are the standard-of-care to recommend unilateral adrenalectomy for presumed unilateral PA. We aimed to assess the rates and characteristics of residual PA after AVS-guided adrenalectomy.&lt;h4>Methods&lt;/h4>We conducted an international, retrospective, cohort study of patients with PA from 7 referral centers who underwent unilateral adrenalectomy based on LI≥4 on baseline and/or cosyntropin-stimulated AVS. Aldosterone synthase (CYP11B2) immunohistochemistry and next generation sequencing were performed on available formalin-fixed paraffin-embedded adrenal tissue.&lt;h4>Results&lt;/h4>The cohort included 283 patients who underwent AVS-guided adrenalectomy, followed for a median of 326 days postoperatively. Lack of PA cure was observed in 16% of consecutive patients, and in 22 patients with lateralized PA on both baseline and cosyntropin-stimulated AVS. Among patients with residual PA postoperatively, 73% had multiple CYP11B2 positive areas within the resected adrenal tissue (versus 23% in those cured), wherein &lt;i>CACNA1D&lt;/i> mutations were most prevalent (63% versus 33% in those cured). In adjusted regression models, independent predictors of postoperative residual PA included Black versus White race (odds ratio, 5.10 [95% CI, 1.45-17.86]), AVS lateralization only at baseline (odds ratio, 8.93 [95% CI 3.00-26.32] versus both at baseline and after cosyntropin stimulation), and CT-AVS disagreement (odds ratio, 2.75 [95% CI, 1.20-6.31]).&lt;h4>Conclusions&lt;/h4>Multifocal, asymmetrical bilateral PA is relatively common, and it cannot be excluded by robust AVS lateralization. Long-term postoperative monitoring should be routinely pursued, to identify residual PA and afford timely initiation of targeted medical therapy.</pubmed_abstract><journal>Hypertension (Dallas, Tex. : 1979)</journal><pubmed_title>Multifocal, Asymmetric Bilateral Primary Aldosteronism Cannot be Excluded by Strong Adrenal Vein Sampling Lateralization: An International Retrospective Cohort Study.</pubmed_title><pmcid>PMC10922262</pmcid><funding_grant_id>R01 HL153004</funding_grant_id><funding_grant_id>R01 DK106618</funding_grant_id><funding_grant_id>R01 DK115392</funding_grant_id><funding_grant_id>R01 HL155834</funding_grant_id><funding_grant_id>K08 CA270385</funding_grant_id><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Salman Z</pubmed_authors><pubmed_authors>Rainey WE</pubmed_authors><pubmed_authors>Williams TA</pubmed_authors><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Satoh F</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Giordano TJ</pubmed_authors><pubmed_authors>Larose S</pubmed_authors><pubmed_authors>Vaidya A</pubmed_authors><pubmed_authors>Dorwal P</pubmed_authors><pubmed_authors>Turcu AF</pubmed_authors><pubmed_authors>Sehgal K</pubmed_authors><pubmed_authors>Tezuka Y</pubmed_authors><pubmed_authors>Wachtel H</pubmed_authors><pubmed_authors>Lim JS</pubmed_authors><pubmed_authors>Parksook WW</pubmed_authors><pubmed_authors>Reincke M</pubmed_authors><pubmed_authors>Lacroix A</pubmed_authors><pubmed_authors>Udager AM</pubmed_authors><pubmed_authors>Cohen DL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Multifocal, Asymmetric Bilateral Primary Aldosteronism Cannot be Excluded by Strong Adrenal Vein Sampling Lateralization: An International Retrospective Cohort Study.</name><description>&lt;h4>Background&lt;/h4>Primary aldosteronism (PA) has been broadly dichotomized into unilateral and bilateral forms. Adrenal vein sampling (AVS) lateralization indices (LI) ≥2 to 4 are the standard-of-care to recommend unilateral adrenalectomy for presumed unilateral PA. We aimed to assess the rates and characteristics of residual PA after AVS-guided adrenalectomy.&lt;h4>Methods&lt;/h4>We conducted an international, retrospective, cohort study of patients with PA from 7 referral centers who underwent unilateral adrenalectomy based on LI≥4 on baseline and/or cosyntropin-stimulated AVS. Aldosterone synthase (CYP11B2) immunohistochemistry and next generation sequencing were performed on available formalin-fixed paraffin-embedded adrenal tissue.&lt;h4>Results&lt;/h4>The cohort included 283 patients who underwent AVS-guided adrenalectomy, followed for a median of 326 days postoperatively. Lack of PA cure was observed in 16% of consecutive patients, and in 22 patients with lateralized PA on both baseline and cosyntropin-stimulated AVS. Among patients with residual PA postoperatively, 73% had multiple CYP11B2 positive areas within the resected adrenal tissue (versus 23% in those cured), wherein &lt;i>CACNA1D&lt;/i> mutations were most prevalent (63% versus 33% in those cured). In adjusted regression models, independent predictors of postoperative residual PA included Black versus White race (odds ratio, 5.10 [95% CI, 1.45-17.86]), AVS lateralization only at baseline (odds ratio, 8.93 [95% CI 3.00-26.32] versus both at baseline and after cosyntropin stimulation), and CT-AVS disagreement (odds ratio, 2.75 [95% CI, 1.20-6.31]).&lt;h4>Conclusions&lt;/h4>Multifocal, asymmetrical bilateral PA is relatively common, and it cannot be excluded by robust AVS lateralization. Long-term postoperative monitoring should be routinely pursued, to identify residual PA and afford timely initiation of targeted medical therapy.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-04T02:45:41.916Z</modification><creation>2025-04-04T02:45:41.916Z</creation></dates><accession>S-EPMC10922262</accession><cross_references><pubmed>38174562</pubmed><doi>10.1161/HYPERTENSIONAHA.123.21910</doi><doi>10.1161/hypertensionaha.123.21910</doi></cross_references></HashMap>